Zlotta AR - Search Results

1

Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.

Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Hersey K, Jewett MA, Zlotta AR, Trachtenberg J, Fleshner NE. Bhindi B, et al. Among authors: zlotta ar. Eur Urol. 2014 Nov;66(5):841-8. doi: 10.1016/j.eururo.2014.06.005. Epub 2014 Jun 18. Eur Urol. 2014. PMID: 24954793

2

Repeat prostate biopsy: who, how and when?. a review.

Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Djavan B, et al. Among authors: zlotta ar. Eur Urol. 2002 Aug;42(2):93-103. doi: 10.1016/s0302-2838(02)00256-7. Eur Urol. 2002. PMID: 12160578 Review.

3

An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.

Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B. Zlotta AR, et al. J Urol. 2003 May;169(5):1724-8. doi: 10.1097/01.ju.0000062548.28015.f6. J Urol. 2003. PMID: 12686818

4

An artificial neural network to predict the outcome of repeat prostate biopsies.

Remzi M, Anagnostou T, Ravery V, Zlotta A, Stephan C, Marberger M, Djavan B. Remzi M, et al. Urology. 2003 Sep;62(3):456-60. doi: 10.1016/s0090-4295(03)00409-6. Urology. 2003. PMID: 12946746 Clinical Trial.

5

Is seminal vesicle ablation mandatory for all patients undergoing radical prostatectomy? A multivariate analysis on 1283 patients.

Zlotta AR, Roumeguère T, Ravery V, Hoffmann P, Montorsi F, Türkeri L, Dobrovrits M, Scattoni V, Ekane S, Bollens R, Vanden Bossche M, Djavan B, Boccon-Gibod L, Schulman CC; European Society for Urological Oncology. Zlotta AR, et al. Eur Urol. 2004 Jul;46(1):42-9. doi: 10.1016/j.eururo.2004.03.021. Eur Urol. 2004. PMID: 15183546

6

Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.

Irani J, Salomon L, Soulié M, Zlotta A, de la Taille A, Doré B, Millet C. Irani J, et al. Urology. 2005 Mar;65(3):533-7. doi: 10.1016/j.urology.2004.10.003. Urology. 2005. PMID: 15780371

7

Prostate cancer prevention: past, present, and future.

Fleshner N, Zlotta AR. Fleshner N, et al. Among authors: zlotta ar. Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009. Cancer. 2007. PMID: 17893870 Free article. Review.

8

Pharmacotherapy for prostate cancer: the role of hormonal treatment.

Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Among authors: zlotta ar. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474 Free article.

9

Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.

Al-Ghamdi AM, Lockwood G, Toi A, Kulkarni GS, Evans A, Finelli A, Zlotta AR, Fleshner N. Al-Ghamdi AM, et al. Among authors: zlotta ar. J Urol. 2008 Apr;179(4):1332-4. doi: 10.1016/j.juro.2007.11.067. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289588

10

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Musquera M, Fleshner NE, Finelli A, Zlotta AR. Musquera M, et al. Among authors: zlotta ar. Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073. Expert Rev Anticancer Ther. 2008. PMID: 18588452 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters